-
Mashup Score: 0
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive opportunity to diagnose, characterize, and monitor the disease in individual cancer patients. ctDNA can reflect the actual tumor burden and specific genomic state of disease and thus might serve as a prognostic and predictive biomarker for immune checkpoint inhibitor (ICI) therapy. Recent studies in various…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis - 3 year(s) ago
Constitutively active estrogen receptor-α (ER/ESR1) mutations have been identified in approximately one third of ER+ metastatic breast cancers. Although these mutations are known mediators of endocrine resistance, their potential role in promoting metastatic disease has not yet been mechanistically addressed. In this study, we show the presence of ESR1 mutations exclusively in distant but not…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study by Li et al shows ESR1 mutations only in distant, but not local recurrences in five independent #BreastCancer cohorts. This supports evidence for ESR1 mutation-mediated metastases and provides insight for preclinical therapeutic strategies. https://t.co/XEB8SKk9v9 https://t.co/XA0Ge8tsgU
-
-
Mashup Score: 1
Immune-modulating systemic therapies are often used to treat advanced cancer such as metastatic clear cell renal cell carcinoma (ccRCC). Used alone, sequence-based biomarkers neither accurately capture patient dynamics nor the tumor immune microenvironment. To better understand the tumor ecology of this immune microenvironment, we quantified tumor infiltration across two distinct ccRCC patient…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ferrall-Fairbanks et al quantify tumor infiltrating T-cell and B-cell diversity of #RenalCellCarcinoma patients and link tumor immune-ecology with #TumorBurden aggressiveness and survival. https://t.co/IJilli8SUy @DrMeghanFerrall @evolsci https://t.co/VC17RNTtHa
-
-
Mashup Score: 2Distribution of Human Papillomavirus Types 16 and 18 Variants in Squamous Cell Carcinomas and Adenocarcinomas of the Cervix - 3 year(s) ago
The distributions of human papillomavirus (HPV) types detected in cervical adenocarcinomas and squamous cell tumors differ. However, whether the distributions of intratypic HPV variants seen in these two histological forms of cervical disease differ is unknown. Our objective was to compare the distribution of HPV intratypic variants observed in squamous cell carcinomas (SCC) and cervical tumors…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Prevalence and predisposition of HPV 16 vs HPV 18 in cervical vs oropharyngeal cancer, and in squamous vs adenocarcinoma. 1️⃣ https://t.co/Zyl44OnBl2 2️⃣ https://t.co/Y2pQ1pbj4J #MedEd #OncTwitter #OncTrainee #HOfellows @HemOncFellows #medtwitter #cancer #hemeonc
-
-
Mashup Score: 2Identification of Active Bronchioalveolar Stem Cells as the Cell-of-Origin in Lung Adenocarcinoma - 3 year(s) ago
While initiation is established as a critical step in tumorigenesis, the identity of the cell-of-origin for lung adenocarcinoma and the mechanism controlling susceptibility to initiation remain elusive. Here we show that lung tumor suppressor Gprc5a-knockout (KO) mice are susceptible to initiation of lung tumorigenesis. Bronchioalveolar stem cells (BASC) and alveolar type 2 (AT2) cells were…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Identification of the cell-of-origin reveals mechanism of lung tumorigenesis and show that Abcg2-positive bronchioalveolar stem cells are candidates for the cell-of-origin in #LungAdenocarcinoma. https://t.co/wfM4m9TC3J https://t.co/tmoSj55UUy
-
-
Mashup Score: 1Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research - 3 year(s) ago
It is only recently that drugs targeting K-RAS and Tp53 missense mutations have been developed, and along with the allele specific nature of some of these drugs comes the possibility of combining them with the immunologic therapies for cancers. It has taken about 40 years since their discoveries to understand the pathways they command, how they function, and how they interact with the environment…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
#OpenAccess Commentary from Arnie Levine in @CR_AACR on translational advances that have been made in targeting mutant p53 in cancer. https://t.co/YkvnNmEldq
-
-
Mashup Score: 0Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition - 3 year(s) ago
Cancer therapy often results in heterogeneous responses in different metastatic lesions in the same patient. Inter- and intra-tumor heterogeneity in signaling within various tumor compartments and its impact on therapy are not well characterized due to the limited sensitivity of single cell proteomic approaches. To overcome this barrier, we applied single cell mass cytometry with a customized…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition | Cancer Research @bcarneiro7 @SheldonLHolder @LanlanZhou #eldeirylab https://t.co/CKj0ko8au2
-
-
Mashup Score: 0
The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revealed unexpected repositioning and cooperation with oncogenic transcription factors, including the…
Source: Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Great paper: Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer @AmerCancerCEO @bcarneiro7 @SheldonLHolder @SeanLawler20 #eldeirylab @LanlanZhou @shengliang15 @carlsen_lindsey https://t.co/xKepn5IziG
-
-
Mashup Score: 7Hypoxia-Inducible Factors in Cancer - 3 year(s) ago
Low oxygen concentrations (hypoxia) are detrimental to most species on Earth; thus, cells have evolved with adaptations allowing them to withstand transient hypoxia. As with other survival pathways, cancer cells have co-opted these mechanisms to keep up with the metabolic demands of rapid growth and proliferation in harsh tumor microenvironments. The most well-studied oxygen response pathway…
Source: Cancer ResearchCategories: Latest Headlines, Oncologists1Tweet-
RT @CR_AACR: Read the latest #CRLandmark: Hypoxia-Inducible Factors in Cancer by Laura C. Kim and M. Celeste Simon. https://t.co/OEVbIYB7VA…
-
-
Mashup Score: 0Hypoxia-Inducible Factors in Cancer - 3 year(s) ago
Low oxygen concentrations (hypoxia) are detrimental to most species on Earth; thus, cells have evolved with adaptations allowing them to withstand transient hypoxia. As with other survival pathways, cancer cells have co-opted these mechanisms to keep up with the metabolic demands of rapid growth and proliferation in harsh tumor microenvironments. The most well-studied oxygen response pathway…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read the latest #CRLandmark: Hypoxia-Inducible Factors in Cancer by Laura C. Kim and M. Celeste Simon. https://t.co/OEVbIYB7VA https://t.co/7PasowxXC0
-
#ReviewArticle by Stadler et al discusses the current and future clinical applications of circulating tumor DNA in #immuno-oncology. https://t.co/nYMNj27UPF https://t.co/CKWx0X9UbJ